GR2102
/ Genrix Bio
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
August 22, 2024
A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2102 in Healthy Adult
(clinicaltrials.gov)
- P1 | N=132 | Recruiting | Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections
March 15, 2024
A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2102 in Healthy Adult
(clinicaltrials.gov)
- P1 | N=132 | Not yet recruiting | Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
New P1 trial • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections
1 to 2
Of
2
Go to page
1